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Abstract
Dengue fever (DF) remains one of the most important emerging infectious diseases. Whereas DF is well recognized in endemic coun-
tries, there are indications that the disease is underdiagnosed among travellers to endemic regions. Here, we present the ﬁrst descrip-
tive survey on cases of travel-acquired DF imported to Denmark diagnosed at the national reference laboratory for dengue virus
diagnostics during a 9-year period. In our study, 16 – 46 travel-acquired dengue virus infections were diagnosed per year. DF is mainly
imported by adults, mostly men, returning from Southeast Asian countries. The minimum incidence of dengue virus infection among
Danish travellers is estimated to be 4.9 per 100 000 travellers. Our results conﬁrm and expand studies from other European countries,
and underline the importance of surveillance based on relevant diagnostic analyses.
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Introduction
Dengue viruses (DENVs) are single-stranded, non-segmented
RNA viruses of the family Flaviviridae. Four distinct serotypes
(DENV-1 to DENV-4) are recognized to be transmitted
between humans by the day-active mosquitoes Aedes aegypti
and Aedes albopictus, which breed in exposed stagnant water
in urban settings [1]. The combination of high population
density and day-active vectors contributes to the high trans-
mission level of DENVs [2].
Dengue fever (DF) is usually a self-limiting febrile disease.
However, in a small percentage of cases, DENV infection
may cause life-threatening complications: dengue haemor-
rhagic fever (DHF) or dengue shock syndrome (DSS) [3].
Infection with one serotype provides life-long immunity
against the homologous serotype, but no cross-protection
against other serotypes. Partial immunity may increase the
risk of severe subsequent DENV infections, including DHF
or DSS [4].
Dengue transmission has expanded dramatically in
recent decades, and DF continues to be one of the most
important emerging diseases, being endemic in more than
100 countries. The WHO estimates that 50 000 000 peo-
ple are infected per year, approximately 500 000 of whom
develop severe disease and are hospitalized [4]. The risk
of infection is higher for the local population in endemic
regions than for the traveller. Nonetheless, many cases of
DENV infection are imported to European countries [5–
11], but the extent of imported DENV infections among
travellers is poorly described and probably underestimated
[3,12].
Until recently, only travel-acquired or imported cases have
been reported in European countries. The autochthonous
transmissions that were reported in France [13] and Croatia
in 2010 [14] emphasize the need for increased attention to
DENV surveillance. Establishment of Ae. albopictus in several
European countries [15] and the continuous importation of
DENV through travelling have increased the risk of such
autochthonous infections.
Our objective was to conduct the ﬁrst descriptive survey
of diagnosed cases of travel-acquired DF imported to Den-
mark during a 9-year period. We have estimated the mini-
mum incidence rate (IR) of DENV infection among Danish
travellers, as travel-acquired DF is probably underdiagnosed.
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Materials and Methods
Ethical considerations
The data for the survey were generated from the routine
DENV diagnostics performed at the Department of Virology,
Statens Serum Institut (SSI), Denmark. The study was
approved by the Danish Data Protection Agency. According
to Danish law (Sundhedsloven), no other ethical committee
approval is required.
Diagnostic procedures
The Department of Virology, SSI, Copenhagen is the Danish
national diagnostic reference laboratory for imported human
viral diseases, and performs ‡80% of all national diagnostic
tests for DENV. All samples received for diagnostic DENV
serology and/or RT-PCR between 2001 and 2009 were
included in the study.
Detection of DENV-speciﬁc IgM and IgG was performed
on all samples included in the study. The detection of viral
RNA (vRNA) by RT-PCR was introduced in the department
on 1 September 2002, and performed on all samples thereaf-
ter. Samples were received from Danish hospitals and >200
general practitioners.
Serology
During the study period, diagnostic serology procedures (IgM
and IgG) were performed, with different assays. From 2001
to 2006, DENV IgM was detected with the Dengue Duo IgM
and IgG rapid strip test (R-DEN02D; PanBio, Queensland,
Australia). In addition, an indirect immunoﬂuorescence assay
was used to detect and titrate DENV-speciﬁc IgG (at the SSI
until 2005, and thereafter at Bernhard-Nocht-Intitut fu¨r
Tropemedizin, Hamburg, Germany). Samples analysed during
2007 to 2008 were tested with the PanBio Dengue Duo cas-
sette kit (R-DEN03D; PanBio). In this period, samples that
were negative for vRNA and IgG but positive for IgM were
conﬁrmed serologically with the Dengue Fever Virus IgM
Capture ELISA (Focus Diagnostics, Cypress, CA, USA), either
at the SSI or at an independent laboratory (Bernhard-Nocht-
Intitut fu¨r Tropemedizin, Hamburg, Germany). Since 2009,
the Dengue Fever Virus ELISA IgG and Dengue Fever Virus
IgM Capture ELISA have been used for primary diagnostic
analysis (40-EL 1500M and 40-EL1500G; Focus Diagnostics).
RT-PCR
Between September 2002 and September 2004, modiﬁed
and previously described serotype-speciﬁc primers [16,17]
were used for the detection and typing of DENV vRNA.
From September 2004 and onwards, DENV vRNA was
detected by real-time RT-PCR, as described elsewhere [18].
Serotypes were determined from RT-PCR results or by
sequence analysis, as described elsewhere [19].
Case deﬁnitions
The case deﬁnition followed the guidelines of the CDC; a
clinically compatible case with laboratory results indicative of
presumptive infection (probable case, e.g. DENV-speciﬁc
IgM) or with conﬁrmatory laboratory results (conﬁrmed
case, e.g. RT-PCR or antigen detection).
Results
During 2001–2009 we have investigated 3181 suspected
cases of DENV infection. After introducing the PanBio
Dengue Duo cassette kit in our routine diagnostic analysis,
we experienced an increased number of samples that were
positive only for DENV-speciﬁc IgM. Therefore, we
decided to conﬁrm these ﬁndings. A total of 76 ‘IgM-only’
samples were retested, and only 17 (22.4%) were con-
ﬁrmed as being IgM-positive and therefore included in this
study.
Following the case deﬁnition of the CDC, we diagnosed a
total of 173 probable cases of DENV infection (13–36 cases
per year) (Fig. 1a). In addition, from 2002 to 2009, we con-
ﬁrmed 114 cases of DENV infection (8–21 cases per year).
There was a trend towards an increase in the number of
cases of DENV infection per year. However, the number of
suspected DF cases (i.e. number of requested analyses)
increased as well during this period, from 292 cases in 2001,
to 469 in 2009. Therefore, the frequency of DF cases had
not increased. The average proportion of conﬁrmed or
probable cases ranged between 6.5% and 13.8% (mean 9.9%)
from 2002 to 2009.
Seasonal variation in suspected and diagnosed cases
During the study period, we found a relatively high propor-
tion of conﬁrmed or probable cases of DENV infection from
April to August (11.2–13.2%), as compared with the other
months (Fig. 1b). There was also a trend towards an
increased number of returning travellers with suspected
DENV infection in March and August. The frequency of posi-
tive samples in August was 11.9%, and this coincides with
the peak of DENV transmission seen in Thailand (http://
www.searo.who.int/en/Section10/Section332_9482.htm). A
lower frequency was detected in March (8.6%). This may be
related to the fact that the countries in which DENV activity
peaks during March (e.g. Indonesia) are generally less visited
by Danish travellers.
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Age and gender distribution
The age distribution of imported DENV cases is shown in
Fig. 2. The mean ages (range) of males and females were
38 years (6–79 years) and 33 years (11–72 years), respec-
tively (n = 365). The overall male/female (M/F) ratio was
1.18 : 1. Among 41–50-year-olds, the M/F ratio was signiﬁ-
cantly skewed (2.2 : 1, v2, p <0.05). Likewise, the calculated
M/F ratio among the 31–50-year-olds was signiﬁcantly
skewed (1.82 : 1, p <0.05).
Laboratory conﬁrmation depends on the time of blood sam-
pling
Information about onset of disease was available only from a
limited number of patients registered between 2004 and
2009 (n = 21). Among this group of patients 75% were
vRNA-positive within the ﬁrst 7 days from onset of symp-
toms, and 50% were positive for IgM (data not shown). Dur-
ing the second week after onset of symptoms, all samples
were IgM-positive, whereas 25% of samples were vRNA-
positive.
Even though the time of onset of symptoms is uncertain,
travel activity information is valuable for interpreting the
results of the analysis. DENV vRNA was detected in the
majority (83%) of the plasma samples (n = 88, 2004–2009)
taken from day 0 to day 7 after return. All samples taken
more than 11 days after return were negative for vRNA,
implying that laboratory conﬁrmation by RT-PCR should not
be expected after this time (Fig. 3). Meanwhile, 62% of the
samples taken during the ﬁrst week after return were sero-
negative.
As expected, the frequency of IgG-positive samples
increased with time from return. All DENV-positive samples
taken ‡2 weeks after return were positive for DENV-speciﬁc
IgG (titres ‡1 : 160).
Most cases are imported from Southeast Asia
Information on travel activity was collected from a total of
95 patients of 195 with probable or conﬁrmed DENV infec-
tion during 2004–2009. The results show that DENV infec-
tions were imported from all endemic continents except
Australia (Australasia) (Table 1). Most cases (67%) were
imported from countries in Southeast Asia, particularly
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FIG. 2. Age distribution of probable or conﬁrmed dengue virus
(DENV) cases in Danish men (black) and women (white) between
2001 and 2009 (n = 365). The asterisk (*) indicates statistically more
common DENV infections among men than among women
(p >0.05).
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FIG. 3. Relationship between time of return from endemic region
and sampling of plasma for dengue virus (DENV) diagnostic tests.
The proportions of samples positive for viral RNA (s), IgM (D) or
IgG (h) are shown.
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FIG. 1. (a) Number of probable (grey) or conﬁrmed (black) dengue
virus (DENV) infections per year. As RT-PCR analysis was intro-
duced in 2002, only probable cases were found in 2001. (b) The sea-
sonal distribution of suspected cases (white) and conﬁrmed or
probable cases (grey). Samples were collected in Denmark between
2001 and 2009.
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Thailand, which are the most visited DENV-endemic destina-
tions for Danish travellers.
Cases of all four serotypes are imported from Thailand
Between 2002 and 2009, the DENV serotype was determined
for 71% of the conﬁrmed cases (n = 87) (Fig. 4). Overall,
DENV-2 was the most frequently detected, whereas DENV-4
was rarely detected, and not at all after 2004. However, coun-
try-speciﬁc differences were observed. In travellers returning
from Indonesia, only DENV-2 was detected. In travellers
returning from the Philippines, India and Bangladesh, we pri-
marily found DENV-2 or DENV-3 infections. DENV-1 was
more frequently found in cases imported from Thailand.
Importantly, all four DENV serotypes were detected in travel-
lers returning from Thailand. Our data also conﬁrm that two
to three different DENV serotypes co-circulated in Thailand
and other countries during most of the study period.
There was one conﬁrmed case of DENV infection per
20 400 Danish travellers to endemic regions
Between 2004 and 2008, the number of Danish travellers to
DENV-endemic countries increased (e.g. from >87 000 to
>151 000 per year for Thailand; http://www.e-unwto.org/
content/v486k6/?v=search). The minimum proportion of
travellers in which DENV infection was conﬁrmed can be
calculated. On the basis of accumulated numbers of travellers
to countries from where most cases have been imported
(Thailand, Indonesia, India, and Bangladesh), we can estimate
an IR of 4.9 (95% CI 3.2–7.2) conﬁrmed cases per 100 000
Danish travellers to endemic areas, or one conﬁrmed DENV
case per 20 400 (31 250–13 890) Danish travellers. The IR
of conﬁrmed or probable DENV infection in the Danish pop-
ulation is 0.57 (0.46–0.67) per 100 000 individuals.
Discussion
We have performed the ﬁrst descriptive study on imported
DENV infections among Danish travellers from 2001 to
2009. The Department of Virology, SSI, Copenhagen per-
forms approximately ‡80% of all national diagnostic testing
for DENV. Fewer than 150 suspected cases are tested sero-
logically each year at major hospitals. In cases of positive
serology, many of these samples are conﬁrmed in our labo-
ratory by RT-PCR. Therefore, the number of probable cases
diagnosed in Denmark is likely to be only slightly higher than
the numbers indicated here.
The increase in the number of DENV cases per year is
probably a consequence of increased exposure resulting from
travelling combined with greater awareness among patients
and physicians, as reﬂected by the increasing numbers of sus-
pected cases. The highest number of cases was found in 2002
(Fig. 1), which coincided with an outbreak in Thailand (http://
www.searo.who.int/en/Section10/Section332_9482.htm).
The number of cases reported in a study from Sweden,
where DENV infection is a notiﬁable disease, is approxi-
mately two-fold to three-fold higher than our results indicate
[20]. In Denmark, DENV infection is not a notiﬁable disease.
Although notiﬁcation does not ensure that all cases are iden-
tiﬁed, it may increase awareness of the disease. Our results
indicate that the number of cases of imported DENV infec-
tion in Denmark may be underestimated. With the recent
TABLE 1. Travel activity of Danish patients with imported
dengue virus infection (2004–2009)
Geographical
region Country
Number of imported
cases
Southeast Asia All 62
Borneoa 2
Indonesia, Bali 9
Indonesia, other 2
Malaysia 2
Philippines 6
Southeast Asiaa 2
Thailand 38
Vietnam 1
South Asia All 19
Bangladesh 6
India 10
Maldives 1
South Asiaa 2
Central America All 6
Central Americaa 2
Costa Rica 3
Nicaragua 1
Africa All 4
Ghana 2
Nigeria 1
Somalia 1
Caribbean All 2
US Virgin Islands 2
South America All 2
Venezuela 2
aCountry not speciﬁed.
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FIG. 4. Serotypes of imported dengue virus (DENV) cases are
shown for each year. DENV-1 (white), DENV-2 (light grey), DENV-3
(dark grey), and DENV-4 (black).
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cases of autochthonous transmission in France and Croatia
[13,14] and the high numbers of tourists visiting European
countries with overwintering expanding populations of
Ae. albopictus [15], we believe that a notiﬁcation system, as in
other EU countries, would be beneﬁcial [8].
The overall M/F gender distribution of probable or con-
ﬁrmed cases in our study is very similar to that in other
reports (Fig. 2) [8]. Between the ages of 31 and 50 years we
found signiﬁcantly more male cases, and this differs some-
what from the distribution in 20 other European countries
combined [21]. The M/F ratio among all tested patients
(positive or negative) was 1.21 : 1, and we found no indica-
tions of signiﬁcant differences in age or gender over the
years. Therefore, the age distribution is likely to represent
the travel activity of the Danish population, rather than any
gender differences in transmission or diagnosis.
The use of different commercial tests for the detection of
DENV IgM showed some discrepancies. Our ﬁndings show
that the number of probable cases may easily be overestimated
if positive IgM test results are not conﬁrmed or complemented
by other diagnostic tests, as discussed earlier [11]. Evaluations
of ELISA test kit performance conducted in our laboratory and
by others show that false-positive IgM results are frequently
obtained with the PanBio Dengue Duo cassette kit [22].
Although the reasons for false IgM-positive results are com-
plex and not fully understood [11], this emphasizes the need
for conﬁrmatory RT-PCR or antigen testing. A number of
studies have indicated that the proportion of DENV infection
is 2–17% among febrile European travellers [9,23,24]. Conse-
quently, given the high transmission level of DENV [2] and the
volume of international travel, patients with acute fever of
short duration should also be asked about recent foreign tra-
vel activity [3]. DENV infection should be considered in all
patients with fever and myalgia returning from endemic areas,
especially in the presence of maculopapular rash, thrombocy-
topenia, increased haematocrit, or elevation of liver enzymes.
Likewise, information on onset of symptoms and return from
endemic regions has important consequences for the diagnosis
of travel-acquired DENV infection, as shown by our study and
other studies [25]. DENV infection may be conﬁrmed by
detection of vRNA, which may be detected up to 11 days after
return. Also, samples from most conﬁrmed cases collected
less than 1 week after return are often seronegative. In symp-
tomatic patients, a negative IgM result does not exclude DENV
infection [26]. We believe that RT-PCR-based diagnosis should
be used together with IgM serology in suspected cases of acute
DENV infection, as suggested by others [3,11,27,28]. Alterna-
tively, NS1 antigen detection may provide conﬁrmation.
Our results show that the majority of Danish imported
DENV infections are acquired in Thailand and other
Southeast Asian travel destinations (Table 1). Other studies
support these ﬁndings [5,7,8,29]. We have demonstrated
transmission of all four serotypes in Thailand, although
transmission of DENV-1 and DENV-2 was more frequent.
Genotype determination of DENV in European travellers
indicates that DEN-1 has been transmitted in Thailand for a
decade, whereas DENV-2 has been found mostly in recent
years. DENV-3 and DENV-4 are also present, but less fre-
quent [30]. Co-circulation of DENV serotypes increases the
risk of severe disease in cases of repeated infections [4].
Obviously, this poses the greatest risk for the local popula-
tion, but is also a risk for visiting travellers with past
DENV infection.
We have estimated that there is one conﬁrmed case of
DENV infection per 20 400 Danish travellers to endemic
regions (4.9 per 100 000 travellers), which is in good agree-
ment with IRs reported from another study [31]. Also, the
IR of the general population is in good agreement with those
of neighbouring countries [21].
Studies of foreign residents and military personnel in
endemic areas suggest that up to one per 1000 may become
infected with DENV during several months of stay (reviewed
in [25,32]). As the risk of infection increase with the length
of stay [7,32], the risk is probably less for the average travel-
ler. The average length of stay is approximately 15 days for
Danish and German travellers in Thailand (http://www2.ta-
t.or.th). In a study from Germany, where DENV infection is
a notiﬁable disease, the IR of conﬁrmed or probable cases of
DENV infection was found to be 8.2–27.9 per 100 000 trav-
ellers [8]. Taking our ﬁndings together, the estimated IR in
our study should be regarded as a minimum proportion. The
true proportion is probably considerably higher, as there is
probably under-reporting of mild cases, as discussed by All-
win et al. [12], and because DENV infection is not a notiﬁ-
able disease in Denmark.
During the study period, we received no information
about haemorrhagic manifestations, shock or death among
Danish travellers with DENV infection. Reports of complica-
tions such as DHF, DSS and fatalities in travellers exist
[5,10], but are generally rare [6,8,20,33]. In one study, haem-
orrhagic manifestations were common [7].
We have conducted a comprehensive survey of the travel-
acquired cases of DENV infection in Denmark, based on data
collected at the national reference laboratory for DENV
over a period of 9 years. The results support ﬁndings from
other European countries, and underline the importance of
considering DENV infection in all febrile patients with recent
travel activity, as well as the timing of sample collection in
relation to the relevance and performance of available labo-
ratory diagnostic tests.
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